Biologics
Lonza and Engitix Partner to Advance Next-Generation ECM-Targeted ADCs
Lonza grants Engitix target-specific license for GlycoConnect®, HydraSpace® and SYNtecan E™ linker-payload technologies for ADC de...
July 21, 2026 | News
The Bioreactors Are Ours. The Consumables Are Not.
A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...
July 21, 2026 | Analysis
Generative Bionics Unveils Gene.01 Humanoid Robot Built in Just Six Months
Built in six months, Gene.01 senses touch, proximity, force, and temperature, and it is released with its open-sourced robot model that gives Physical AI d...
July 21, 2026 | News
Rege Nephro Raises $10.6M to Advance iPS Cell-Based Kidney Disease Pipeline
inancing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline Rege Nephro Co., Ltd. ("Rege Nephr...
July 21, 2026 | News
Vector Partners with Caresyntax to Build Real-World Evidence Programme for Opioid-Sparing Surgical Platform
Caresyntax will design and operate a multi-phase real-world evidence program for Vector, culminating in a prospective comparative reg...
July 21, 2026 | News
China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer
SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...
July 21, 2026 | News
Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced NSCLC
Akeso, Inc. (9926.HK) (announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2...
July 21, 2026 | News
Samsung Biologics Launches CHF 1.46B All-Cash Bid to Acquire PolyPeptide
Samsung Biologics to launch an all-cash public tender offer for 100% of PolyPeptide's fully diluted share capital (excluding therefrom any treasury share...
July 21, 2026 | News
Canada and Taiwan Build New Bridges Across AI, Advanced Therapeutics and Precision Health
As biotechnology increasingly converges with artificial intelligence, advanced therapeutics and data-driven healthcare, the next generation of inno...
July 20, 2026 | News
Why Korea, Why Now? Korean Biotech Looks to Taiwan as Asia’s Next Partnership Frontier
Korea’s biotechnology industry is entering a new phase of global ambition. Having established significant capabilities across biopharmaceutical manuf...
July 20, 2026 | News
Creative Life Science Showcases Regenerative Medicine Manufacturing Capabilities at BIO Asia–Taiwan 2026
BIO Asia-Taiwan 2026 opens July 16 at the Taipei Nangang Exhibition Center and runs through July 19. Creative Life Science (7837) is showcasing its upstrea...
July 20, 2026 | News
Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...
July 20, 2026 | News
Telix Advances Illuccix Towards Japan Approval After Completing Phase III Patient Enrollment
Completed enrollment of 105 patients in Phase 3 registration study of TLX591-Px (Illuccix®) for prostate cancer imaging in Japan. The study data wil...
July 20, 2026 | News
From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing
ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As ...
July 17, 2026 | Expert Insight
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
